Bright Minds Biosciences (DRUG) EBITDA (2019 - 2026)
Bright Minds Biosciences (DRUG) EBITDA from Dec 31, 2019 to Mar 31, 2026. The TTM Bright Minds Biosciences (DRUG) EBITDA is -$20M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Bright Minds Biosciences (DRUG) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +654.16% |
| 3 Years TTM | +38.90% |
| 5 Years TTM | +57.53% |
| All Time TTM | +83.49% |
Annual EBITDA change of Bright Minds Biosciences (DRUG)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$7.63M | -12.64% |
| 2025 | -$8.73M | +332.39% |
| 2024 | -$2.02M | -62.46% |
| 2023 | -$5.38M | -50.31% |
| 2022 | -$11M | +56.59% |
| 2021 | -$6.91M | +1857.96% |
| 2020 | -$353K | +484.05% |
| 2019 | -$60K | N/A |
Comparison Bright Minds Biosciences (DRUG) five years EBITDA CAGR with competitors
Bright Minds Biosciences (DRUG) five years EBITDA CAGR is 57.52%.